{"created":"2015-05-15T13:34:19+00:00","modified":"2015-05-15T13:34:19+00:00","valid":{"from":"2013-04-11T13:24:11+00:00","to":"3013-04-11T13:24:11+00:00"},"hreflang":"en","guid":"e3ce4b0b-ed99-49b6-82d5-cdef18df24c8","tags":["APM","Economy","Mid-day Update"],"byline":"Jeremy Hobson","published":"2013-04-11T13:24:11+00:00","teaser":"Water wars heat up in New Mexico. CEO of Biogen Idec discusses high drug costs, a new drug for multiple sclerosis and what's up with pharmaceutical drug names.","contentencoded":"<div class=\"barn-cleaned\"><p>The drought has dried up water supplies in some parts of the country -- and <a href=\"http://www.marketplace.org/topics/sustainability/farmers-vs-cities-war-water\" target=\"_blank\">water wars are heating up</a>, between farmers and cities. In New Mexico, farmers have kicked off what could be a long-running fight by making a “priority call” on water resources.</p>\n<p><a href=\"http://www.biogenidec.com/\" target=\"_blank\">Biogen Idec</a>, a Massachusetts-based biotech company, is hoping its new multiple sclerosis drug <a href=\"http://www.tecfidera.com/index.html?utm_source=google&amp;utm_medium=cpc&amp;utm_campaign=Branded+-+Tecfidera&amp;utm_term=tecfidera&amp;utm_content=General%7Cmkwid%7CsizwNqPjR%7Cpcrid%7C20563887307\" target=\"_blank\">Tecfidera</a> will eventually bring in the hundreds of millions of dollars it cost to develop -- at least before a generic comes along and copies it. CEO George Scangos joined Marketplace Morning Report host Jeremy Hobson to <a href=\"http://www.marketplace.org/topics/tech/health-care/biogen-idec-ceo-drug-costs-and-taking-multiple-sclerosis\" target=\"_blank\">discuss his company's development process and pricing strategy.</a></p></div>","description":"Water wars heat up in New Mexico. CEO of Biogen Idec discusses high drug costs, a new drug for multiple sclerosis and what's up with pharmaceutical drug names.","itags":["Marketplace","Marketplace Morning Report for Thursday, April 11, 2013","e3ce4b0bed999b622d57cdef18df24c8","PMP:Marketplace_PMP","Marketplace Morning Report"],"title":"PODCAST: Water war, Biotech industry core","contenttemplated":"[{\"type\":\"text/html\",\"content\":\"<p>The drought has dried up water supplies in some parts of the country -- and <a href=\\\"http://www.marketplace.org/topics/sustainability/farmers-vs-cities-war-water\\\" target=\\\"_blank\\\">water wars are heating up</a>, between farmers and cities. In New Mexico, farmers have kicked off what could be a long-running fight by making a “priority call” on water resources.</p>\"},{\"type\":\"text/html\",\"content\":\"<p><a href=\\\"http://www.biogenidec.com/\\\" target=\\\"_blank\\\">Biogen Idec</a>, a Massachusetts-based biotech company, is hoping its new multiple sclerosis drug <a href=\\\"http://www.tecfidera.com/index.html?utm_source=google&amp;utm_medium=cpc&amp;utm_campaign=Branded+-+Tecfidera&amp;utm_term=tecfidera&amp;utm_content=General%7Cmkwid%7CsizwNqPjR%7Cpcrid%7C20563887307\\\" target=\\\"_blank\\\">Tecfidera</a> will eventually bring in the hundreds of millions of dollars it cost to develop -- at least before a generic comes along and copies it. CEO George Scangos joined Marketplace Morning Report host Jeremy Hobson to <a href=\\\"http://www.marketplace.org/topics/tech/health-care/biogen-idec-ceo-drug-costs-and-taking-multiple-sclerosis\\\" target=\\\"_blank\\\">discuss his company&apos;s development process and pricing strategy.</a></p>\"}]","audio":[{"type":"image/jpeg","href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/93186079.jpg?itok=oLjW8TkI","meta":{"crop":"primary","height":"340","width":"610"}},{"meta":{"duration":430,"duration_hms":"00:07:10","api":{"href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/morning_report/2013/04/11/marketplace_morning_report_full_20130411","type":"application/json"}},"format":"MP3","href":"http://play.publicradio.org/pmp/d/podcast/marketplace/morning_report/2013/04/11/marketplace_morning_report_full_20130411_64.mp3","type":"audio/mpeg"}]}